Cardiology

Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.

Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.

A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.

SGLT2 inhibitor therapy provided protective effects from cardiovascular (CV) events in patients with type 2 diabetes with or without established CV disease.

Amlodipine lowered the risk of gout when compared with 2 other antihypertensive medications.

Ticagrelor (Brilinta, AstraZeneca) reduced the risk of stroke and death when taken with aspirin compared with aspirin alone.

Administration time for warfarin did not affect the stability of the drug’s anticoagulation effect, a new study showed. 

The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.

Individuals with a history of heart disease may be at an increased risk of developing kidney failure.

Are the benefits of lowering systolic blood pressure to less than 130 mm Hg the same for those aged 80 years and older as they are for younger patients?

AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.

A new study examined diabetes as an independent predictor of heart failure. 

The approvals were granted to generic apixaban applications from Micro Labs Limited and Mylan Pharmaceuticals Inc.

Invasive methods did not perform better than drug treatment in patients with stable ischemic heart disease

Officials with the FDA have approved a new indication and label expansion for icosapent ethyl (Vascepa, Amarin).

Pharmacist-led initiatives, such as medication therapy management, for chronic diseases can significantly improve patient outcomes.

First and currently only biological targeting P-selectin.

Statin regimens may need tweaking to deliver optimal results. 

Approved in May 2019, granted to FoldRx, a subsidiary of Pfizer.

Reduces risk for heart failure and cardiovascular disease hospitalizations.

Also indciated to control bleeding and perioperative management.

Black box warns of increased risk of blood clots and death.

Fourth approval for use in assessing myocardial perfusion and late gadolinium enhancement.

Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.

Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.